can you take glp-1 with thyroid issues Medications & Disease Patients Who Lose Weight After

It is currently scheduled to run from July 1, 2026 through December 31, 2027

Nausea and appetite suppression are the most common side effects during the first few weeks of treatment

FDA-approved GLP-1 medications are administered via subcutaneous injection (semaglutide, liraglutide, dulaglutide, tirzepatide) into the abdomen, thigh, or upper arm, or taken orally as Rybelsus

These multifaceted actions contribute to both improved glycemic control and weight reduction, which has made this drug class particularly valuable for patients with type 2 diabetes who are overweight or obese

Diarrhea Occurs in approximately 15-25% of patients

A 2022 systematic review and meta-analysis published in JAMA Internal Medicine found that GLP-1 receptor agonists were associated with increased risks of biliary disease compared to other diabetes medications, with higher risk observed at weight-loss doses and with longer duration of treatment